Effect of intravenous clarithromycin in patients with sepsis, respiratory and multiple organ dysfunction syndrome: a randomized clinical trial

Table 2 Study clinical outcomes

	Clarithromycin (n = 55)	Placebo (n = 55)	OR for clarithromycin	P value
Primary outcome, n (%, 95% CI)
Mortality at 28 days	27 (49.1, 35.5–62.8)	25 (45.5, 32.2–59.3)	1.157 (0.547–2.448)	0.849
Secondary outcomes
Mortality at 90 days, n (%, 95% CI)	41 (74.5, 60.7–84.9)	38 (69.1, 55.0–80.5)	1.310 (0.569–3.016)	0.672
Early sepsis response on day 3, n (%, 95% CI)	18 (32.7, 21.1–46.8)	23 (41.8, 28.9–55.9)	0.677 (0.311–1.473)	0.430
Sepsis response on day 7, n (%, 95% CI)	23 (41.8, 28.9–55.9)	28 (50.9, 37.2–64.5)	0.693 (0.327–1.471)	0.445
New sepsis episode until day 28^a, n (%, 95% CI)	7 (30.4, 14.1–53.0)	19 (67.9, 47.6–83.4)	0.207 (0.063–0.682)	0.012
Days to new sepsis episode up to day 28, mean (SD)^a n (%, 95% CI)	18 (7)	15 (6)	–	0.368

CI, confidence intervals; OR, odds ratio; and SD, standard deviation
^aAmong 51 patients experiencing sepsis response, defined by SOFA decrease of ≥ 25% on day 7

ISSN: 1364-8535